GlassScriptPhysician profile
James Daton Rooke
NPI 1578529426
$1,619.44
in general payments reported to CMS, 2019-2025
20 companies · $396 in 2025
The $396 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $462 · 2020: $83.34 · 2021: $38.81 · 2022: $32.91 · 2023: $133 · 2024: $473 · 2025: $396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $962 · Long Term Medical Supply Or Device Loan: $39.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $961.97 |
| Long Term Medical Supply Or Device Loan | $39.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $358.33 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Novo Nordisk INC | $216.90 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $180.36 | 2019-2025 | Jardiance |
| Dexcom, INC. | $130.87 | 2019-2024 | Dexcom G6 Transmitter |
| Tandem Diabetes Care, INC. | $118.62 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Lilly USA, LLC | $116.30 | 2019-2025 | Zepbound |
| Abbott Laboratories | $89.90 | 2024-2025 | Freestyle Libre 3, Freestyle Insulinx |
| Medtronic, INC. | $75.99 | 2024-2025 | Minimed 780g |
| Ascendis Pharma Endocrinology INC | $70.25 | 2025 | Yorvipath |
| Amgen INC. | $49.91 | 2019-2024 | Prolia, Evenity |
| Merck Sharp & Dohme LLC | $34.94 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $29.09 | 2019 | |
| Insulet Corporation | $26.83 | 2025 | Omnipod |
| Kaleo, INC. | $24.61 | 2019 | |
| Lifescan, INC. | $21.04 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $18.99 | 2023 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $17.31 | 2020 | |
| Amarin Pharma, INC. | $15.49 | 2019 | |
| Pfizer INC. | $11.88 | 2019 | |
| Acorda Therapeutics, INC | $11.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Rooke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.